GREY:ATBPF - Post Discussion
Post by
Duster340 on Nov 15, 2023 9:48am
2 new target prices
Antibe Therapeutics (ATBPF)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Antibe Therapeutics, with a price target of C$2.00. The company’s shares closed last Tuesday at $0.64.
Antibe Therapeutics (ATBPF)
Echelon Wealth Partners analyst Stefan Quenneville maintained a Buy rating on Antibe Therapeutics today and set a price target of C$2.00. The company’s shares closed last Monday at $0.66.
Be the first to comment on this post